• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Family-Building Costs, Barriers and Dropout Rates Associated With Fertility Care

Opinion
Video

Janet Choi, MD, analyzes fertility care access, balancing the significant benefits of evidence-based reproductive treatment against the economic obstacles that restrict patient utilization of safe, effective interventions known to improve outcomes.

This is a video synopsis/summary of a Population Health Perspectives® involvingJanet Choi, MD.The video discusses the substantial financial barriers to fertility treatment, with costs ranging from $15,000 to $30,000 per in vitro fertilization cycle. A survey found 77% of LGBTQ+ individuals pursuing parenthood worried about family-building costs. Of those lacking adequate insurance, many tapped savings or took loans, adding stress. However, the speaker argues comprehensive coverage reduces patient emotional/financial tolls. Initially skeptical clients realize savings of 25% to 30% over traditional programs, without accounting for boosted recruitment/retention and productivity and lower absenteeism from improved benefits. Janet Choi, MD,maintainsthat adding inclusive fertility coverage costs less than expected, with dividends for diversity, equity and inclusion. With rising infertility prevalence and assisted reproductive technology reliance among LGBTQ+ prospective parents, innovative smart cycle value-based configurations are gaining favor. Such end-to-end individual coverage is superior to limited dollar caps that burden patients withtracking service expenses to fit budgets, distorting clinical decisions. Comprehensive smart cycle benefits ease anxiety about affording prescribed treatments so patients can focus fully on building families.

Video synopsis is AIgenerated and reviewed by Managed Healthcare Executive® editorial staff.

Related Videos
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Video 8 - "Risk and Value-Based Contracting for Prescription Drug Therapeutics and Manufacturer’s Support in Utilization"
Video 7 - "Prescribing Prescription Drug Therapeutics: Factors for Providers and Payers to Consider"
Video 9 -"Overcoming Implementation Barriers for Digital Therapeutics Adoption"
Video 6 - "Failing to Reach Ideal Diabetes Care: Equitable Doesn’t Mean Equal"
Video 5 - "Revising Diabetes Outcome Measures"
Video 6 - "Navigating Insurance Coverage for Prescription Digital Therapeutics"
© 2024 MJH Life Sciences

All rights reserved.